{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:07:47Z","timestamp":1786982867246,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T00:00:00Z","timestamp":1770768000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008899","name":"University of South Carolina","doi-asserted-by":"crossref","award":["100014638"],"award-info":[{"award-number":["100014638"]}],"id":[{"id":"10.13039\/100008899","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100005349","name":"American Association of Colleges of Pharmacy","doi-asserted-by":"publisher","award":["10012653"],"award-info":[{"award-number":["10012653"]}],"id":[{"id":"10.13039\/100005349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s40801-026-00542-0","type":"journal-article","created":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T05:26:33Z","timestamp":1770787593000},"page":"145-152","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Age and Gender Heterogeneity in Adverse Drug Reactions Associated with Hemp Use: Evidence from the FDA Pharmacovigilance Data in the Last Two Decades"],"prefix":"10.1007","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9239-2125","authenticated-orcid":false,"given":"Chengwen","family":"Teng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z. Kevin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,11]]},"reference":[{"key":"542_CR1","unstructured":"US Congress. Agriculture Improvement Act of 2018 (Public Law 115-334). https:\/\/www.govinfo.gov\/content\/pkg\/PLAW-115publ334\/html\/PLAW-115publ334.htm. Accessed 12 Sept 2025."},{"key":"542_CR2","volume-title":"The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research","author":"National Academies of Sciences, Engineering, and Medicine","year":"2017","unstructured":"National Academies of Sciences, Engineering, and Medicine. The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research. Washington, DC: The National Academies Press; 2017."},{"issue":"1","key":"542_CR3","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1089\/can.2018.0006","volume":"3","author":"J Corroon","year":"2018","unstructured":"Corroon J, Phillips JA. A cross-sectional study of cannabidiol users. Cannabis Cannabinoid Res. 2018;3(1):152\u201361. https:\/\/doi.org\/10.1089\/can.2018.0006.","journal-title":"Cannabis Cannabinoid Res"},{"issue":"10","key":"542_CR4","doi-asserted-by":"publisher","first-page":"974","DOI":"10.2174\/1570159X17666190603171901","volume":"17","author":"MA Huestis","year":"2019","unstructured":"Huestis MA, Solimini R, Pichini S, Pacifici R, Carlier J, Busardo FP. Cannabidiol adverse effects and toxicity. Curr Neuropharmacol. 2019;17(10):974\u201389. https:\/\/doi.org\/10.2174\/1570159X17666190603171901.","journal-title":"Curr Neuropharmacol"},{"issue":"7","key":"542_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/jcm8070989","volume":"8","author":"JD Brown","year":"2019","unstructured":"Brown JD, Winterstein AG. Potential adverse drug events and drug-drug interactions with medical and consumer cannabidiol (CBD) use. J Clin Med. 2019;8(7):989. https:\/\/doi.org\/10.3390\/jcm8070989.","journal-title":"J Clin Med"},{"issue":"6","key":"542_CR6","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/2045125312457586","volume":"2","author":"Z Atakan","year":"2012","unstructured":"Atakan Z. Cannabis, a complex plant: different compounds and different effects on individuals. Ther Adv Psychopharmacol. 2012;2(6):241\u201354. https:\/\/doi.org\/10.1177\/2045125312457586.","journal-title":"Ther Adv Psychopharmacol"},{"issue":"1","key":"542_CR7","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1159\/000507998","volume":"3","author":"PT Kocis","year":"2020","unstructured":"Kocis PT, Vrana KE. Delta-9-tetrahydrocannabinol and cannabidiol drug-drug interactions. Med Cannabis Cannabinoids. 2020;3(1):61\u201373. https:\/\/doi.org\/10.1159\/000507998.","journal-title":"Med Cannabis Cannabinoids"},{"issue":"21","key":"542_CR8","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMoa1611618","volume":"376","author":"O Devinsky","year":"2017","unstructured":"Devinsky O, Cross JH, Laux L, et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N Engl J Med. 2017;376(21):2011\u201320. https:\/\/doi.org\/10.1056\/NEJMoa1611618.","journal-title":"N Engl J Med"},{"issue":"11","key":"542_CR9","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1038\/s41386-020-0667-2","volume":"45","author":"E Chesney","year":"2020","unstructured":"Chesney E, Oliver D, Green A, et al. Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials. Neuropsychopharmacology. 2020;45(11):1799\u2013806. https:\/\/doi.org\/10.1038\/s41386-020-0667-2.","journal-title":"Neuropsychopharmacology"},{"issue":"17","key":"542_CR10","doi-asserted-by":"publisher","first-page":"1708","DOI":"10.1001\/jama.2017.11909","volume":"318","author":"MO Bonn-Miller","year":"2017","unstructured":"Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. Labeling accuracy of cannabidiol extracts sold online. JAMA. 2017;318(17):1708\u20139. https:\/\/doi.org\/10.1001\/jama.2017.11909.","journal-title":"JAMA"},{"key":"542_CR11","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.copsyc.2019.04.002","volume":"30","author":"TR Spindle","year":"2019","unstructured":"Spindle TR, Bonn-Miller MO, Vandrey R. Changing landscape of cannabis: novel products, formulations, and methods of administration. Curr Opin Psychol. 2019;30:98\u2013102. https:\/\/doi.org\/10.1016\/j.copsyc.2019.04.002.","journal-title":"Curr Opin Psychol"},{"issue":"3","key":"542_CR12","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/bph.12362","volume":"171","author":"F Franconi","year":"2014","unstructured":"Franconi F, Campesi I. Pharmacogenomics, pharmacokinetics and pharmacodynamics: interaction with biological differences between men and women. Br J Pharmacol. 2014;171(3):580\u201394. https:\/\/doi.org\/10.1111\/bph.12362.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"542_CR13","doi-asserted-by":"publisher","DOI":"10.1186\/s13293-020-00308-5","volume":"11","author":"I Zucker","year":"2020","unstructured":"Zucker I, Prendergast BJ. Sex differences in pharmacokinetics predict adverse drug reactions in women. Biol Sex Differ. 2020;11(1):32. https:\/\/doi.org\/10.1186\/s13293-020-00308-5.","journal-title":"Biol Sex Differ"},{"issue":"1","key":"542_CR14","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/npp.2017.140","volume":"43","author":"ZD Cooper","year":"2018","unstructured":"Cooper ZD, Craft RM. Sex-dependent effects of cannabis and cannabinoids: a translational perspective. Neuropsychopharmacology. 2018;43(1):34\u201351. https:\/\/doi.org\/10.1038\/npp.2017.140.","journal-title":"Neuropsychopharmacology"},{"issue":"8","key":"542_CR15","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.29074","volume":"6","author":"T Rushovich","year":"2023","unstructured":"Rushovich T, Gompers A, Lockhart JW, et al. Adverse drug events by sex after adjusting for baseline rates of drug use. JAMA Netw Open. 2023;6(8):e2329074. https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.29074.","journal-title":"JAMA Netw Open"},{"key":"542_CR16","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.drugalcdep.2018.07.006","volume":"191","author":"BH Han","year":"2018","unstructured":"Han BH, Palamar JJ. Marijuana use by middle-aged and older adults in the United States, 2015-2016. Drug Alcohol Depend. 2018;191:374\u201381. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.07.006.","journal-title":"Drug Alcohol Depend"},{"issue":"5","key":"542_CR17","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1017\/S1041610210002176","volume":"23","author":"DM Dinitto","year":"2011","unstructured":"Dinitto DM, Choi NG. Marijuana use among older adults in the U.S.A.: user characteristics, patterns of use, and implications for intervention. Int Psychogeriatr. 2011;23(5):732\u201341. https:\/\/doi.org\/10.1017\/S1041610210002176.","journal-title":"Int Psychogeriatr"},{"key":"542_CR18","unstructured":"US Food and Drug Administration. FDA's Adverse Event Reporting System (FAERS). https:\/\/www.fda.gov\/drugs\/surveillance\/fdas-adverse-event-reporting-system-faers. Accessed 12 Sept 2025."},{"issue":"11","key":"542_CR19","doi-asserted-by":"publisher","first-page":"1504","DOI":"10.7150\/ijms.38605","volume":"16","author":"C Teng","year":"2019","unstructured":"Teng C, Baus C, Wilson JP, Frei CR. Rhabdomyolysis associations with antibiotics: a pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS). Int J Med Sci. 2019;16(11):1504\u20139. https:\/\/doi.org\/10.7150\/ijms.38605.","journal-title":"Int J Med Sci"},{"issue":"5","key":"542_CR20","doi-asserted-by":"publisher","first-page":"630","DOI":"10.7150\/ijms.30739","volume":"16","author":"C Teng","year":"2019","unstructured":"Teng C, Reveles KR, Obodozie-Ofoegbu OO, Frei CR. Clostridium difficile infection risk with important antibiotic classes: an analysis of the FDA Adverse Event Reporting System. Int J Med Sci. 2019;16(5):630\u20135. https:\/\/doi.org\/10.7150\/ijms.30739.","journal-title":"Int J Med Sci"},{"issue":"7","key":"542_CR21","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.7150\/ijms.34141","volume":"16","author":"C Teng","year":"2019","unstructured":"Teng C, Walter EA, Gaspar DKS, Obodozie-Ofoegbu OO, Frei CR. Torsades de pointes and QT prolongation associations with antibiotics: a pharmacovigilance study of the FDA Adverse Event Reporting System. Int J Med Sci. 2019;16(7):1018\u201322. https:\/\/doi.org\/10.7150\/ijms.34141.","journal-title":"Int J Med Sci"},{"issue":"1","key":"542_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1007\/s40801-021-00268-1","volume":"9","author":"C Teng","year":"2022","unstructured":"Teng C, Frei CR. Delirium associations with antibiotics: a pharmacovigilance study of the FDA Adverse Event Reporting System (FAERS). Drugs Real World Outcomes. 2022;9(1):23\u20139. https:\/\/doi.org\/10.1007\/s40801-021-00268-1.","journal-title":"Drugs Real World Outcomes"},{"issue":"6","key":"542_CR23","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, et al. The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): development and statement. Drug Saf. 2024;47(6):575\u201384. https:\/\/doi.org\/10.1007\/s40264-024-01421-9.","journal-title":"Drug Saf"},{"issue":"6","key":"542_CR24","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1002\/pds.1742","volume":"18","author":"A Bate","year":"2009","unstructured":"Bate A, Evans SJ. Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf. 2009;18(6):427\u201336. https:\/\/doi.org\/10.1002\/pds.1742.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"6","key":"542_CR25","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans SJ, Waller PC, Davis S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol Drug Saf. 2001;10(6):483\u20136. https:\/\/doi.org\/10.1002\/pds.677.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"12","key":"542_CR26","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S2215-0366(19)30401-8","volume":"6","author":"N Black","year":"2019","unstructured":"Black N, Stockings E, Campbell G, et al. Cannabinoids for the treatment of mental disorders and symptoms of mental disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2019;6(12):995\u20131010. https:\/\/doi.org\/10.1016\/S2215-0366(19)30401-8.","journal-title":"Lancet Psychiatry"},{"issue":"8-9","key":"542_CR27","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1016\/j.lfs.2012.06.009","volume":"92","author":"RM Craft","year":"2013","unstructured":"Craft RM, Marusich JA, Wiley JL. Sex differences in cannabinoid pharmacology: a reflection of differences in the endocannabinoid system? Life Sci. 2013;92(8\u20139):476\u201381. https:\/\/doi.org\/10.1016\/j.lfs.2012.06.009.","journal-title":"Life Sci"},{"issue":"10208","key":"542_CR28","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1016\/S0140-6736(19)31789-1","volume":"394","author":"W Hall","year":"2019","unstructured":"Hall W, Stjepanovic D, Caulkins J, et al. Public health implications of legalising the production and sale of cannabis for medicinal and recreational use. Lancet. 2019;394(10208):1580\u201390. https:\/\/doi.org\/10.1016\/S0140-6736(19)31789-1.","journal-title":"Lancet"},{"issue":"1","key":"542_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s42238-025-00310-x","volume":"7","author":"S Plebon-Huff","year":"2025","unstructured":"Plebon-Huff S, Aziz N, Cavar M, et al. Trends in cannabis adverse reaction reports: a descriptive analysis of spontaneous reporting data submitted to the Canada Vigilance Program since legalization and regulation of cannabis for non-medical purposes in Canada. J Cannabis Res. 2025;7(1):56. https:\/\/doi.org\/10.1186\/s42238-025-00310-x.","journal-title":"J Cannabis Res"},{"key":"542_CR30","unstructured":"Government of Canada. Data on cannabis adverse reactions: overview of annual reports. https:\/\/www.canada.ca\/en\/health-canada\/services\/publications\/drugs-health-products\/data-cannabis-adverse-reactions-reports-overview.html. Accessed 13 Jan 2026."},{"key":"542_CR31","unstructured":"Government of Canada. Cannabis adverse reaction reporting for licence holders: general information. https:\/\/www.canada.ca\/en\/health-canada\/services\/publications\/drugs-health-products\/cannabis-adverse-reaction-reporting-licence-holders.html. Accessed 13 Jan 2026."},{"issue":"7","key":"542_CR32","doi-asserted-by":"publisher","first-page":"796","DOI":"10.7150\/ijms.6048","volume":"10","author":"T Sakaeda","year":"2013","unstructured":"Sakaeda T, Tamon A, Kadoyama K, Okuno Y. Data mining of the public version of the FDA adverse event reporting system. Int J Med Sci. 2013;10(7):796\u2013803. https:\/\/doi.org\/10.7150\/ijms.6048.","journal-title":"Int J Med Sci"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00542-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-026-00542-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-026-00542-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T14:40:17Z","timestamp":1773931217000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-026-00542-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,11]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["542"],"URL":"https:\/\/doi.org\/10.1007\/s40801-026-00542-0","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,11]]},"assertion":[{"value":"27 January 2026","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2026","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Chengwen Teng, Jun Wu, Jing Yuan, and Z. Kevin Lu have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The Institutional Review Board of The University of South Carolina determined that this study is not human subject research (IRB number: Pro00101342). This study was conducted in accordance with the Declaration of Helsinki.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The raw data supporting the conclusions of this article will be made available by the authors, without undue reservation.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The software codes used in this study will be made available by the authors, without undue reservation.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Study concept and design: CT, JW, JY, ZKL. Statistical analysis: CT. Interpretation of data: CT, JW, JY, ZKL. Drafting of the manuscript: CT, ZKL. Critical revision of the manuscript for important intellectual content: CT, JW, JY, ZKL. Study supervision: CT, ZKL. All authors read and approved the final version.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}